Filing identity and period
Important: The supplied filing is Ocuphire Pharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023 (filed May 15, 2023), not a filing identified as Opus Genetics, Inc. The filing reports ticker OCUP and describes a clinical-stage ophthalmic biopharmaceutical company.
Business context
Ocuphire is developing therapies for retinal and refractive eye disorders. Its lead retinal candidate is APX3330; its refractive candidate Nyxol is licensed to Viatris, which assumed the partner’s obligations after acquiring FamyGen in January 2023. The company had no approved products and depended on cash, collaboration reimbursements, and potential future financing and licensing revenue.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| License and collaboration revenue | $1.749 million | None; increase of $1.749 million |
| Research and development expense | $5.595 million | $4.772 million; up $0.823 million |
| General and administrative expense | $2.285 million | $1.736 million; up $0.549 million |
| Total operating expenses | $7.880 million | $6.508 million; up $1.372 million |
| Operating loss | $6.131 million | $6.508 million |
| Net loss | $5.791 million; $0.28 per share | $6.595 million; $0.35 per share |
| Cash used in operating activities | $3.646 million | $6.170 million |
| Cash and cash equivalents | $38.988 million at March 31, 2023 | $42.634 million at December 31, 2022 |
| Total liabilities | $4.154 million | $2.753 million at December 31, 2022 |
Q1 2023 revenue came from Nyxol research and development cost reimbursements, not product sales. The company reported $340,000 of other income, primarily interest income, and no interest expense. No income tax benefit was recognized. Cash declined by $3.646 million during the quarter; there was no financing cash flow in Q1 2023. The filing reports no outstanding debt at quarter-end. Cash exceeded current liabilities, and management said available cash was expected to fund planned expenditures and obligations for at least 12 months after May 15, 2023.
Material changes and developments
- Net loss narrowed by $804,000 year over year, despite higher operating expenses, supported by Nyxol reimbursement revenue and improved other income.
- R&D expense rose with increased manufacturing activity for Nyxol and APX3330 and higher payroll and consulting costs. G&A rose primarily due to stock compensation, professional and legal services, and business development.
- Cash and cash equivalents fell $3.646 million from year-end. Accounts receivable increased to $2.834 million; the Nyxol contract asset was $2.467 million.
- On April 19, 2023, after quarter-end, the company terminated CEO Mina Sooch and appointed Richard Rodgers interim CEO. His letter agreement provides a $40,000 monthly salary and 50,000 restricted stock units, subject to vesting.
Outlook, risks, and contingencies
- APX3330: The January 2023 ZETA-1 Phase 2 trial did not meet its primary endpoint, but achieved statistical significance on a prespecified secondary endpoint measuring binocular diabetic retinopathy worsening. The company planned an FDA End-of-Phase 2 meeting in the second half of 2023 to discuss the endpoint and next steps. The trial showed a favorable safety and tolerability profile, according to the filing.
- Nyxol: The FDA accepted the NDA for reversal of pharmacologically induced mydriasis; the PDUFA action date was September 28, 2023. Approval would trigger a $10 million milestone from Viatris. Topline VEGA-2 Phase 3 presbyopia results were expected in late 2023; further Viatris-funded trials were planned. These were expectations, not guaranteed outcomes.
- Under the Nyxol agreement, Viatris reimburses budgeted U.S. development costs through FDA approval. The company recognized $1.749 million of revenue in Q1; remaining milestone and royalty amounts were constrained and no such revenue was recognized.
- Management expects R&D expenses to increase as development advances. The company may need additional capital; financing could dilute shareholders, impose debt covenants, or require granting rights on unfavorable terms. Clinical, regulatory, manufacturing, and commercialization outcomes are uncertain, and the company cautioned it may never achieve profitability or positive operating cash flow.
- Cash was held largely at one financial institution; deposits exceeded federally insured limits by $38.7 million. Management cited macroeconomic, inflation, banking-market, and capital-market uncertainty as potential risks to costs and financing access.
- Potential Apexian development, regulatory, and sales milestones total up to $31 million, plus single-digit royalties, but none were triggered or considered probable at quarter-end. The filing reported no material legal proceedings and no recorded loss contingencies.
No formal revenue, earnings, or cash-flow guidance was provided. Management’s liquidity statement was based on current plans and is subject to development costs and financing uncertainty.
Key facts for investors to verify
- Confirm the issuer: this document is Ocuphire Pharma’s 10-Q, not an Opus Genetics filing.
- Track the FDA’s September 28, 2023 action date for Nyxol and whether the $10 million approval milestone becomes payable.
- Assess the FDA’s feedback on APX3330’s failed primary endpoint, the secondary endpoint, and the planned End-of-Phase 2 discussion.
- Monitor cash use, Viatris reimbursement collections, and whether the stated 12-month runway remains adequate as trial spending increases.
- Review dilution exposure: 5,665,838 Series A warrants and 1,538,461 RDO warrants were outstanding at March 31, 2023; options and other share-based awards also contribute to potential dilution.
- Evaluate the leadership transition and the concentration of uninsured cash deposits.